Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Validation & Orientation for MAC Disease

At a Glance

MAC disease is a chronic infection from environmental nontuberculous bacteria that usually affects vulnerable lungs. Its pattern, symptoms, scans, and sputum results guide whether to monitor closely or use several antibiotics, often for at least a year after cultures turn negative.

Learning you have Mycobacterium avium complex (MAC) can feel overwhelming, especially because it is a condition many people—including some healthcare providers—have never heard of. It is important to know that while MAC is serious and requires specialized care, it is not a “hidden” form of tuberculosis, nor is it a reflection of your personal hygiene [1][2].

Understanding the MAC Diagnosis

MAC is a group of bacteria belonging to the non-tuberculous mycobacteria (NTM) family [3]. Unlike the bacteria that cause tuberculosis (TB), MAC is found naturally all around us in the environment, particularly in soil and water systems [2]. It is generally not considered a person-to-person infection; you likely encountered these bacteria in your daily life through water vapor or dust [4].

Because MAC is uncommon, you may find that local doctors have limited experience with it. In the contiguous United States, estimates suggest that between 1.4 and 13.9 people per 100,000 are living with pulmonary NTM disease [5]. In certain regions, like Hawaii, the rate can be as high as 44 per 100,000 [5]. This rarity means that finding a specialist who focuses on NTM can be a vital step in your care.

Why You and Why Now?

One of the most common reactions to a MAC diagnosis is to wonder what you did “wrong.” It is critical to understand that MAC does not happen because of poor hygiene or a “dirty” home, and routine home sterilization is not required. Most people breathe in these bacteria every day without getting sick [2]. For a MAC infection to take hold in the lungs, there usually needs to be a “host susceptibility”—a reason your lungs were more vulnerable to the bacteria [6].

Common factors that make it easier for MAC to stay in the lungs include:

  • Structural Lung Changes: The most common factor is bronchiectasis, a condition where the airways in the lungs are widened and scarred, making it harder to clear out mucus and bacteria [6][7].
  • Physical Characteristics: MAC is often associated with people of a slender build (a low body mass index) or certain chest wall shapes, such as pectus excavatum (a sunken breastbone) [8][9]. These are just associations, not a treatment you can fix by yourself.
  • Immune and Genetic Factors: Underlying immune variations or significant immune dysfunction (like advanced HIV or anti-interferon-gamma autoantibodies) can sometimes make it harder for the body to fight this specific group of bacteria [9][10]. Many patients, however, have no single identifiable immune defect.

The Course of the Disease

MAC is generally a slow-moving, chronic condition [11]. Your care team will likely spend time determining your specific phenotype—the way the disease looks and behaves in your body [12].

There are two main ways MAC appears on imaging:

  1. Nodular Bronchiectatic: This is often a slower form where the bacteria cause small nodules and inflamed airways [13]. In many cases, doctors may choose to monitor this form through “watchful waiting.” This requires a documented close-follow-up plan and clear triggers to start treatment, rather than just waiting [12].
  2. Cavitary: This is a more aggressive form where the bacteria create “cavities” or holes in the lung tissue [14]. This form usually requires more immediate and intensive treatment [15].

What to Expect Long-Term

Because MAC is persistent, the typical disease course is measured in months and years, not days [13]. If you and your doctor decide to start treatment, it often involves a combination of three or more antibiotics taken for at least 12 months after your sputum cultures turn negative [16][17].

Even after successful treatment, it is common for the bacteria to return—not necessarily because the treatment failed, but because the same environmental factors or lung vulnerabilities that led to the first infection are still present [18]. This is why long-term follow-up and focus on “airway clearance” (techniques to keep the lungs clear of mucus) are often lifelong parts of living with MAC [19]. Although the journey is long, many patients live stable, active lives by working closely with a specialist to manage the condition [13].

Common questions in this guide

What is MAC disease, and is it the same as tuberculosis?
MAC disease is caused by Mycobacterium avium complex, a group of environmental bacteria in the nontuberculous mycobacteria family. It is not a hidden form of tuberculosis and is generally not passed from person to person or caused by poor hygiene.
Why did I develop MAC lung disease?
MAC usually takes hold when the lungs have a vulnerability that makes it harder to clear bacteria, with bronchiectasis being a common factor. Low body mass index, pectus excavatum, immune problems, and certain immune antibodies can also be associated with MAC, although many people have no single identifiable immune defect.
What is the difference between nodular bronchiectatic and cavitary MAC disease?
Nodular bronchiectatic disease causes small lung nodules and inflamed, widened airways and often progresses more slowly. Cavitary disease creates holes in lung tissue, tends to be more aggressive, and usually calls for more immediate and intensive treatment.
Does everyone with MAC lung disease need antibiotics right away?
No. Some people with slower nodular bronchiectatic disease may be managed with structured watchful waiting based on symptoms, scans, and sputum results. Monitoring should include a clear follow-up schedule and agreed signs that would prompt treatment.
How long does treatment for MAC disease usually last?
Treatment often uses a combination of three or more antibiotics. When treatment is started, it commonly continues for at least 12 months after sputum cultures become negative, although the plan depends on the individual's disease pattern and response.
Can MAC disease return after treatment?
Yes, MAC can return even after successful treatment. Recurrence may happen because environmental exposure and underlying lung vulnerabilities remain, so long-term follow-up and airway-clearance practices are often important.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific phenotype of MAC lung disease do I have—nodular bronchiectatic or cavitary—and how many lobes of my lungs are involved?
  2. 2.Based on my symptoms and CT scans, do we need to start treatment, or is a structured 'watchful waiting' plan an appropriate option?
  3. 3.What is my current body mass index (BMI), and are there nutritional goals I should aim for to help my body fight this infection?
  4. 4.How many cases of MAC or other non-tuberculous mycobacteria do you treat each year?
  5. 5.Do I have any underlying conditions, like bronchiectasis or immune factors, that made me more susceptible to this infection?
  6. 6.If we decide to monitor my condition, what is the schedule for follow-up imaging and sputum cultures to ensure we don't miss signs of progression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Varying clinical presentations of nontuberculous mycobacterial disease : Similar to but different from tuberculosis.

    Shinohara T, Morizumi S, Sumitomo K

    The journal of medical investigation : JMI 2021; (68(3.4)):220-227 doi:10.2152/jmi.68.220.

    PMID: 34759134
  2. 2

    Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex.

    Nishiuchi Y, Iwamoto T, Maruyama F

    Frontiers in medicine 2017; (4()):27 doi:10.3389/fmed.2017.00027.

    PMID: 28326308
  3. 3

    Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.

    PMID: 32636299
  4. 4

    Showering is associated with Mycobacterium avium complex lung disease: An observational study in Japanese women.

    Uwamino Y, Nishimura T, Sato Y, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2020; (26(3)):211-214 doi:10.1016/j.jiac.2019.09.003.

    PMID: 31604605
  5. 5

    Epidemiology of Nontuberculous Mycobacteriosis.

    Adjemian J, Daniel-Wayman S, Ricotta E, Prevots DR

    Seminars in respiratory and critical care medicine 2018; (39(3)):325-335 doi:10.1055/s-0038-1651491.

    PMID: 30071547
  6. 6

    Risk Factors for the Development of Nontuberculous Mycobacteria Pulmonary Disease during Long-Term Follow-Up after Lung Cancer Surgery.

    Kim BG, Choi YS, Shin SH, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(5)) doi:10.3390/diagnostics12051086.

    PMID: 35626242
  7. 7

    Non-tuberculous mycobacteria (NTM) and COPD: a multicentre prospective study.

    Tabernero E, Aramburu A, Sanchez R, et al.

    BMJ open respiratory research 2025; (12(1)) doi:10.1136/bmjresp-2025-003691.

    PMID: 41436243
  8. 8

    Lady Windermere Syndrome Presenting As Prolonged Febrile Illness in an Immunocompetent Woman.

    Romero Merino P, Lerzundi Mamani ML, Cipion-Bueno E, et al.

    Cureus 2026; (18(6)):e110224 doi:10.7759/cureus.110224.

    PMID: 42403832
  9. 9

    Host Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease.

    Namkoong H, Holland SM

    Clinics in chest medicine 2023; (44(4)):723-730 doi:10.1016/j.ccm.2023.07.002.

    PMID: 37890911
  10. 10

    The Mycobacterium avium complex - an underestimated threat to humans and animals.

    Kaczmarkowska A, Didkowska A, Kwiecień E, et al.

    Annals of agricultural and environmental medicine : AAEM 2022; (29(1)):22-27 doi:10.26444/aaem/136398.

    PMID: 35352901
  11. 11

    Treatment of Mycobacterium avium Complex (MAC).

    Griffith DE

    Seminars in respiratory and critical care medicine 2018; (39(3)):351-361 doi:10.1055/s-0038-1660472.

    PMID: 30071550
  12. 12

    Treatment for Mycobacterium avium complex lung disease.

    Pan SW, Shu CC, Feng JY, Su WJ

    Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119 Suppl 1()):S67-S75 doi:10.1016/j.jfma.2020.05.006.

    PMID: 32446754
  13. 13

    The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.

    Kwon BS, Lee JH, Koh Y, et al.

    Respiratory medicine 2019; (150()):45-50 doi:10.1016/j.rmed.2019.02.007.

    PMID: 30961950
  14. 14

    Long-Term Treatment Outcome of Progressive Mycobacterium Avium Complex Pulmonary Disease.

    Fukushima K, Kitada S, Abe Y, et al.

    Journal of clinical medicine 2020; (9(5)) doi:10.3390/jcm9051315.

    PMID: 32370226
  15. 15

    Mycobacterium avium Complex Disease.

    Daley CL

    Microbiology spectrum 2017; (5(2)) doi:10.1128/microbiolspec.TNMI7-0045-2017.

    PMID: 28429679
  16. 16

    [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].

    Wagner D, Lange C

    Deutsche medizinische Wochenschrift (1946) 2020; (145(16)):1145-1151 doi:10.1055/s-0043-124159.

    PMID: 32791550
  17. 17

    Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease.

    Griffith DE, Adjemian J, Brown-Elliott BA, et al.

    American journal of respiratory and critical care medicine 2015; (192(6)):754-60 doi:10.1164/rccm.201503-0444OC.

    PMID: 26068042
  18. 18

    Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility.

    Boyle DP, Zembower TR, Qi C

    Annals of the American Thoracic Society 2016; (13(11)):1956-1961 doi:10.1513/AnnalsATS.201605-344BC.

    PMID: 27599038
  19. 19

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943

This page provides educational information about MAC disease and does not replace medical advice. Ask an NTM-experienced clinician to interpret your scans, cultures, risk factors, and treatment options.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.